Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 121
Pediatric Hematology Oncology Journal ; 7(2):41-44, 2022.
Article in English | EMBASE | ID: covidwho-2321859


Coronavirus disease-19 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic and is giving rise to a serious health threat globally. SARS-CoV-2 infection ranges from asymptomatic carrier state to severe illness requiring intensive care unit (ICU) management. It is postulated that with COVID-19 infection, children are less prone to develop severe symptoms as compared with adults. The data on immunocompromised children affected with COVID-19 infection is limited and not many publications are there on the effects of 2nd wave of COVID-19 infection in pediatric hematology/oncology patients till date. In our experience during second wave, 17 patients were found to be positive for SARS-CoV-2 with a male: female ratio of 2.4: 1 and median age of 8 years (range 1-18 years). Out of these 17 patients, 10 (58.8%) patients required hospital admission whereas the remaining were managed at home. Only 1 patient required ventilatory support and there was no mortality. Though the number of pediatric patients with COVID-19 infection were more during the second wave but majority had mild to moderate symptoms and were easily managed.Copyright © 2022 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics

Endocrine Practice ; 29(5 Supplement):S4, 2023.
Article in English | EMBASE | ID: covidwho-2319635
Lung Cancer ; 178(Supplement 1):S74, 2023.
Article in English | EMBASE | ID: covidwho-2317957
Journal of Cancer Metastasis and Treatment ; 7 (no pagination), 2021.
Article in English | EMBASE | ID: covidwho-2316239
Gynecologic Oncology Reports ; 44(Supplement 2):S5, 2022.
Article in English | EMBASE | ID: covidwho-2298841
ESMO Open ; Conference: The ESMO Gynaecological Cancers Congress 2023. Barcelona Spain. 8(1 Supplement 1) (no pagination), 2023.
Article in English | EMBASE | ID: covidwho-2295083
Annals of Surgical Oncology ; 30(Supplement 1):S128, 2023.
Article in English | EMBASE | ID: covidwho-2294985
Psycho Oncology Conference: 20th Annual Conference of the American Psychosocial Oncology Society Portland, OR United States ; 32(Supplement 1), 2023.
Article in English | EMBASE | ID: covidwho-2291377
Journal of Clinical Oncology ; 41(4 Supplement):255, 2023.
Article in English | EMBASE | ID: covidwho-2260397
Journal of Consumer Health on the Internet ; 27(1):73-85, 2023.
Article in English | Scopus | ID: covidwho-2249243
Clinical Trials ; 20(Supplement 1):3-4, 2023.
Article in English | EMBASE | ID: covidwho-2280125
Journal of Clinical Oncology ; 41(6 Supplement):134, 2023.
Article in English | EMBASE | ID: covidwho-2276692
Cancer Epidemiology Biomarkers and Prevention Conference: 15th AACR Conference onthe Science of Cancer Health Disparities in Racial/Ethnic Minoritiesand the Medically Underserved Philadelphia, PA United States ; 32(1 Supplement), 2023.
Article in English | EMBASE | ID: covidwho-2236184


Background: Following George Floyd's murder in May 2020, conversations about equity and bias became part of our daily national conversation. Simultaneously the COVID-19 outbreak disproportionately affected people of color which further illuminated existing disparities in outcomes. Bias training was introduced in many sectors as a strategy to address inequity. Inclusivity in healthcare is essential to develop evidence-based therapies and treatment plans. Previous studies have demonstrated the consequences when racial and ethnic minorities are excluded from research. (Hamel et al, 2016). Racial and ethnic minorities disproportionately bear adverse outcomes from cancer. Cancer clinical trials would benefit from solutions to promote inclusivity. (Khan et al. 2021) Research Purpose: The purpose of our study was to assess whether Implicit Bias Training can increase minority participation in cancer clinical trials. Methodology: The Office of Diversity, Equity, and Inclusion offered Implicit Bias Training to all clinical oncologists at the Yale Cancer Center (YCC) between May and July 2021. While 109 physicians were eligible to participate, 57 physicians were required by the department to complete this training, and 84% of these physicians completed this opportunity. We analyzed YCC clinical trial enrollment data between two time periods defined as pre-intervention and post-intervention. We selected these periods to investigate not only the efficacy of bias training but specifically bias training as an adjunct to the national conversation during the time of our study. We selected the preintervention period as January 1, 2021, to June 30, 2021. The intervention was designed to be completed by July 1, 2021 therefore the post-intervention period is defined as July 1, 2021 to December 31, 2021. Results/Summary: Our analysis showed an increase of 2.5% in the participation of Black/African American patients. There was a slight (1.5%) decrease in Hispanic patient enrollment during this time. Conclusion(s): Our analysis suggested that implicit bias training delivered once had only a very modest, if any, improvement in racial minority participation in cancer clinical trials. Our project focused on participation by Black/African American patients. The impediment to Hispanic participation is quite nuanced. Hispanic patients, many of whom are non-English speaking with immigration/insurance issues face additional structural barriers. We think that a different strategy is needed to better serve this patient population. While we had hoped for metrics to demonstrate greater impact from bias training, our next investigation will look at if the intervention is best delivered repeatedly. Future Work: We have not abandoned the strategy of bias training to build trust and increase Black/AA participation. After the intervention, we are interested in whether greater impact is seen over time. We have designed a survey to look at the effects of the intervention after a year. Our next step is to examine whether repeated delivery of this intervention will amplify our results.